Andrius Žučenka: Congratulations to All the Investigators Involved in the PARADIGM trial
Andrius Žučenka, Assistant professor at Vilniaus universitetas / Vilnius University, shared a post on LinkedIn:
“First and foremost, huge congratulations to all the investigators and everyone involved in the Paradigm trial, the hottest acute myeloid leukemia (AML) topic at the American Society of Hematology 2025. King 7+3 took a massive blow. But has lord HMA+Ven truly won?
Before reading further I sincerely recommend listening to the most recent Wolverheme podcast.
Bernard Marini and Anthony Perissinotti superbly analyzed the presented abstract in such great detail, that there’s no point for me to go through specific trial data here, (KUDOS, guys). I want to simply present my few thoughts from a general/our center’s perspective.”
Read full paper here.
Get the latest updates on Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation